Aller au contenu principal
Profil bibliographique

A. Moskowitz

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

15Publications signalées
162Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCNS Lymphoma Diagnosis and TreatmentViral-associated cancers and disorders

Les publications récentes

Accès ouvert 2025 article OpenAlex

757 | INCIDENCE OF MYELOID NEOPLASMS IN PATIENTS WITH T‐FOLLICULAR HELPER CELL LYMPHOMAS

Ken-Kuo Lin, Nivetha Ganesan, Yan Ma, Ting‐Chang Chang et autres

Conclusions: Despite the finding that nodal TFH lymphomas develop on a background of CH, the cumulative incidence of subsequent MN is relatively low.This finding may be due to a high competing risk of death from lymphoma, use of allogeneic transplant in the …

us (code pays fourni par la source)

0 citations Hematological Oncology
Accès ouvert 2025 article OpenAlex

734 | REAL‐WORLD OUTCOMES OF FRONTLINE BRENTUXIMAB VEDOTIN IN OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐AN INTERNATIONAL, MULTI‐CENTER STUDY

Efrat Luttwak, Esther Drill, Nivetha Ganesan, Liron Hofstetter et autres

Introduction: Despite favorable outcomes in younger pts with cHL, those aged ≥ 60, have inferior survival, due to disease biology (e.g., mixed cellularity, EBVþ, advanced-stage disease) and comorbidities impacting treatment-related toxicity.Brentuximab vedotin (BV) plus AVD (doxorubicin, vinblastine, dacarbazine) is approved for frontline …

us, il (code pays fourni par la source)

0 citations Hematological Oncology
Accès ouvert 2025 article OpenAlex

182 | GENOMIC TESTING IN PATIENTS WITH LARGE CELL AND FOLLICULAR LYMPHOMA TREATED WITH T‐CELL ENGAGERS BI‐SPECIFIC ANTIBODIES AND CORRELATION WITH TREATMENT RESPONSE

Rita Tavarozzi, Michelle Okwali, Maria E. Arcila, Annie Qiu et autres

rearrangement would have a prognostic impact, the high variability in the non-IgH MYC partner requires further investigation of the impact of these fusion genes.

it, us (code pays fourni par la source)

0 citations Hematological Oncology
Accès ouvert 2025 article OpenAlex

394 | RUXOLITINIB TARGETS STAT1‐STAT3 COOPERATIVELY IN LARGE GRANULAR LYMPHOCYTIC LEUKEMIA

Amira Marouf, Simon Grassmann, Jahan Rahman, Nivetha Ganesan et autres

endpoint was progression-free survival (PFS).CD/RCD status was confirmed by duodenal histology, flow cytometry and TCR gene rearrangement of IELs, celiac serology, and HLA typing.Results: Between February 2018 and February 2021, 14 patients were enrolled (median age: 54 years [34-65]; 64% male).Eleven underwent …

us (code pays fourni par la source)

1 citation Hematological Oncology
Accès ouvert 2025 article OpenAlex

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

Danilo Fiore, Luca Vincenzo Cappelli, Nikita Kotlov, Maria Sorokina et autres

Peripheral T cell lymphomas (PTCLs) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived tumor xenografts (PDXs) retaining histomorphology and molecular donor-tumor features over serial xenografting. PDX demonstrates remarkable heterogeneity, complex intratumor architecture, …

us, it, cn, il, ch, ru (code pays fourni par la source)

11 citations Cell Reports Medicine
2019 article OpenAlex

MULTI‐CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC‐486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T‐CELL LYMPHOMA

Jia Ruan, John P. Leonard, Melanie Coleman, Sarah C. Rutherford et autres

Introduction: Peripheral T-cell lymphomas (PTCL) are an uncommon and heterogeneous group of non-Hodgkin lymphomas with divergent cells of origin and mechanisms of lymphomagenesis. Cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, the most commonly prescribed initial treatment for systemic PTCL, provides suboptimal complete …

us (code pays fourni par la source)

1 citation Hematological Oncology
Accès ouvert 2017 article OpenAlex

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

Connie Lee Batlevi, Anna Alperovich, Ai Ni, Jacob D. Soumerai et autres

Introduction: Management of follicular lymphoma (FL) requires multiple lines of therapy despite improved outcomes. We sought to 1) define treatment outcomes after multiple lines of therapy and 2) examine impact of FLIPI score changes on the outcome of initially observed patients. Methods: …

us, gb, cn (code pays fourni par la source)

1 citation Hematological Oncology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.